@HealthCapVC

HealthCap is a family of venture capital funds investing globally in life sciences and is one of the largest life science specialized VC's in Europe.

healthcap.eu
Joined November 2012
  • Tweets1.3K
  • Following30
  • Followers967
6Media
Dear friends of @HealthCapVC. We will suspend our Twitter. Communications will be through our website healthcap.eu and Linked-In linkedin.com/company/healthc…. Please follow us there.

Start - HealthCap

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

healthcap.eu
1
1
Priothera - Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy healthcap.eu/ycmp
2
Oncopeptides’ Pepaxti has been granted marketing authorization in the UK healthcap.eu/eyn9
1
3
Oncopeptides announces the market potential for Pepaxti in Europe healthcap.eu/7c2w
1
1
Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21 healthcap.eu/k36j
3
2
Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership healthcap.eu/0om5
1
Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen healthcap.eu/t21w
1
6
BONESUPPORT’s CERAMENT®G used in first U.S. patient cases healthcap.eu/ceec
3
Targovax - The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info healthcap.eu/lxyf
2
2
Vicore selects new ATRAG as next Drug Candidate healthcap.eu/tui7
2
Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study healthcap.eu/ykv5
1
3
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth healthcap.eu/rgch
1
Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market healthcap.eu/4m0u
1
4
Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA healthcap.eu/vdpo
1
3
Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC healthcap.eu/wo57
Vicore announces that C21 promotes vascular function in humans healthcap.eu/0nsc
3
Sesen Bio and Carisma Therapeutics Announce Merger Agreement healthcap.eu/dinm
3
Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published healthcap.eu/ik81
Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease healthcap.eu/gj3l
1
Vicore provides an update on the ATTRACT-3 COVID-19 trial healthcap.eu/gtzr
Load more